"Loading Stock Price & Valuation Data ..."
Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to IMRX. [ FAQ on what and how to ask] For non-IMRX questions, click the logo in the upper-right corner to return to the main page and ask there.
CEO:Dr. Benjamin J. Zeskind M.B.A., Ph.D.
Headquarter: 245 Main Street, Second Floor, Cambridge, MA, United States, 02142
Industry: Biotechnology, Employees: 54
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
My Watchlist
